Therion Biologics Corporation develops therapeutic vaccines that aim to extend and improve the lives of cancer patients. The company has two lead product candidates: PANVAC-VF, entering a Phase III clinical trial for pancreatic cancer; and PROSTVAC®-VF in a Phase II clinical trial for prostate cancer. The company is applying its technology to develop its vaccine pipeline, including treatments for breast cancer, lung cancer, and the prevention of AIDS. Therion is also developing a vaccine for colon cancer with its strategic partner, Aventis Pasteur, Ltd. Through Therion's longstanding partnerships with the National Cancer Institute (NCI) and a network of renowned clinical institutions, over 700 patients in more than 30 clinical trials have been treated with Therion's vaccine candidates.
The Therion Advantage
Therion is well positioned to commercialize the next generation of cancer therapeutics as a fully integrated, clinical-stage biotechnology company, with strong research, clinical, and manufacturing capabilities.
Therion's advantages include:
Over 30 clinical trials conducted to support optimized lead candidate development;
Novel technology with extensive patent coverage, including over 70 issued patents;
Strong investor support, including a $40 million private financing in 2003;
Seasoned management team with demonstrated clinical and commercial success;
Fully integrated infrastructure, including a new manufacturing facility built to GMP specifications.
|
